John Marshall, MD, discusses the individualization of treatment of patients with colorectal cancer (CRC).
John Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, discusses the individualization of treatment of patients with colorectal cancer (CRC). Marshall says while maintaining VEGF-inhibition does promote a better overall survival advantage, there is not a major difference between many of the frontline therapies. He adds that the order in which medical professionals decide to use these treatments is entirely up to the individual and based on what the patient responds to.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Creating Solutions for a 'Continual State of Transition' in Cancer Care
April 15th 2024In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.
Read More